Skip to main contentSkip to navigationSkip to search

Curasight - Providing answers for cancer patients

On a mission improving cancer care for millions of lives

We are a Danish biotech company developing a more gentle and efficient cancer care. Our team are the pioneers behind the novel uPAR Theranostics technology. A technology that minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.​

About us

Latest press releases

All press releases

How our technology works

Curasight was listed on Spotlight Stock Market in October 2020. See the information video from the initial public explaining how the technology works.

Be part of funding the cancer treatment of tomorrow

With aging populations, increased number of cancers, wider use of nuclear medicine and introductions of new radiopharmaceuticals around the world as growth factors, the market is expected to grow rapidly. Based on promising results, Curasight’s Board and management projects that their technology could become game-changing in the management of cancer patients.